The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease
Objective: A clinical audit of apomorphine pumps – The Indian experience. Background: Continuous dopaminergic therapy remains crucial in the management of moderately advanced Parkinson’s disease…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease
Objective: To establish and characterize a robust alpha-synuclein (aSyn) aggregation pathology research model to allow efficient drug development platform for Parkinson's disease (PD). Background: PD…The cold hand sign in multiple system atrophy: prevalence, associated factors and impact on survival
Objective: The purpose of the study was to investigate the prevalence of and factors associated with cold hand sign in multiple system atrophy (MSA) patients,…Clinical profile and cerebral metabolic characteristic of cognitive impairments in multiple system atrophy
Objective: This study aimed to characterize the cognitive profiles of multiple system atrophy (MSA) and explore the possible mechanisms involved using 18F-fluorodeoxyglucose (FDG) Positron Emission…Decline in the midbrain-to-pons ratio over one year can support the differentiation between PSP and IPD
Objective: The midbrain-to-pons ratio (MTPR) is considered as an important diagnostic biomarker to differentiate between progressive supranuclear palsy (PSP) and idiopathic Parkinson’s disease (IPD). Here,…Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism
Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…Burden of Care-Partners of People with Parkinson’s Disease: Findings from Parkinson’s Disease Real-World Impact Assessment (PRISM) Study
Objective: To evaluate the characteristics and burden of the care-partners of people with Parkinson’s disease (PwP). Background: The burden of care-partners of PwP is currently…Clinical outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency (PTPSd)
Objective: To assess morbility and clinical outcome of patients affected by defect of tetrahydrobiopterin (BH4) synthesis due to PTPSd. Background: PTPSd is a treatable genetic disorder…
- « Previous Page
- 1
- …
- 89
- 90
- 91
- 92
- 93
- …
- 149
- Next Page »